Last reviewed · How we verify
HAI-05 Influenza Vaccine
HAI-05 Influenza Vaccine is a Biologic drug developed by Fraunhofer, Center for Molecular Biotechnology. It is currently in Phase 1 development.
At a glance
| Generic name | HAI-05 Influenza Vaccine |
|---|---|
| Sponsor | Fraunhofer, Center for Molecular Biotechnology |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HAI-05 Influenza Vaccine CI brief — competitive landscape report
- HAI-05 Influenza Vaccine updates RSS · CI watch RSS
- Fraunhofer, Center for Molecular Biotechnology portfolio CI
Frequently asked questions about HAI-05 Influenza Vaccine
What is HAI-05 Influenza Vaccine?
HAI-05 Influenza Vaccine is a Biologic drug developed by Fraunhofer, Center for Molecular Biotechnology.
Who makes HAI-05 Influenza Vaccine?
HAI-05 Influenza Vaccine is developed by Fraunhofer, Center for Molecular Biotechnology (see full Fraunhofer, Center for Molecular Biotechnology pipeline at /company/fraunhofer-center-for-molecular-biotechnology).
What development phase is HAI-05 Influenza Vaccine in?
HAI-05 Influenza Vaccine is in Phase 1.